Organization Profile

You just read:

Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic Hepatitis B and Delta

News provided by

Russian Venture Company

Oct 21, 2014, 04:00 ET